[Clinical studies on apalcillin in biliary tract infections (author's transl)].
Clinical studies on apalcillin (APPC), a new broad spectrum semisynthetic penicillin developed in Japan, were carried out, and the following results were obtained. APPC was administered to three patients with serious biliary tract infections by intramuscular or intravenous injection at daily dosage of 2. Therapeutic responses were excellent in all cases, and no side effects and abnormalities of laboratory findings were observed. APPC was considered to be an excellent drug for the treatment of biliary tract infections.
D000328:Adult; D000667:Ampicillin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002761:Cholangitis / Q000188:drug therapy; D002764:Cholecystitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000008:administration & dosage / Q000627:therapeutic use
D009287:Naphthyridines; C012122:apalcillin; D000667:Ampicillin